Posttranslational modification

Proteinase K Market Size Worth $110.43 Million By 2027 | CAGR: 7.6%: Grand View Research, Inc.

Retrieved on: 
Monday, October 19, 2020
Proteinase K, Posttranslational modification, Protease

SAN FRANCISCO, Oct. 19, 2020 /PRNewswire/ -- The global proteinase K market is expected to reach USD 110.43 million by 2027, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Oct. 19, 2020 /PRNewswire/ -- The global proteinase K market is expected to reach USD 110.43 million by 2027, according to a new report by Grand View Research, Inc.
  • Proteinase K is a serine protease commonly applied in the digestion of proteins and the removal of contaminants during nucleic acid preparations.
  • Pretreatment with Proteinase K removes the requirement for performing the entire standard protocol for purification and extraction of a COVID-19 sample.
  • Grand View Research has segmented the global proteinase K market based on therapeutic area, form, and region:
    Proteinase K Therapeutic Area Outlook (Revenue, USD Million, 2016 - 2027)

Proteinase K Market Size Worth $110.43 Million By 2027 | CAGR: 7.6%: Grand View Research, Inc.

Retrieved on: 
Monday, October 19, 2020
Proteinase K, Posttranslational modification, Protease

SAN FRANCISCO, Oct. 19, 2020 /PRNewswire/ -- The global proteinase K market is expected to reach USD 110.43 million by 2027, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Oct. 19, 2020 /PRNewswire/ -- The global proteinase K market is expected to reach USD 110.43 million by 2027, according to a new report by Grand View Research, Inc.
  • Proteinase K is a serine protease commonly applied in the digestion of proteins and the removal of contaminants during nucleic acid preparations.
  • Pretreatment with Proteinase K removes the requirement for performing the entire standard protocol for purification and extraction of a COVID-19 sample.
  • Grand View Research has segmented the global proteinase K market based on therapeutic area, form, and region:
    Proteinase K Therapeutic Area Outlook (Revenue, USD Million, 2016 - 2027)

Mogrify Introduces EpiMOGRIFY Platform to Systematically Identify Epigenetic Switches Driving Cell Identity and Cell Maintenance

Retrieved on: 
Friday, October 9, 2020
Biotechnology, Genetics, Health, Clinical trials, Branches of biology, Biology, Genetics, Posttranslational modification, Cellular processes, Induced stem cells, Molecular genetics, Cellular differentiation, Epigenetics, H3K4me3, Histone methylation, Bivalent chromatin

The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.

Key Points: 
  • The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.
  • EpiMOGRIFY is an extension of the Companys proprietary direct cellular conversion technology, MOGRIFY, and enables the identification of the optimal culture conditions required to maintain cells in chemically defined media.
  • EpiMOGRIFY combines gene-regulatory information with a model of a cells epigenetic landscape and leverages changes in the level of DNA-histone methylation (H3K4me3 modifications).
  • The predictive power of EpiMOGRIFY has been validated in two ways: cell maintenance and differentiation.

Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit

Retrieved on: 
Tuesday, October 6, 2020
Posttranslational modification, Metabolism, Proteolysis

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced thatJohn Houston, Ph.D., President and Chief Executive Officer, will present a keynote plenary session at the 3rd Annual Targeted Protein Degradation Summit being held virtually October 14-15, 2020.

Key Points: 
  • NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced thatJohn Houston, Ph.D., President and Chief Executive Officer, will present a keynote plenary session at the 3rd Annual Targeted Protein Degradation Summit being held virtually October 14-15, 2020.
  • The presentation will reflect on Arvinas advances in its PROTAC platform and introduce new pipeline programs.
  • Title: The Promise of PROTAC Protein Degraders: Whats Next for Arvinas Pipeline & Platform
    Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
  • Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the bodys own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit

Retrieved on: 
Tuesday, October 6, 2020
Branches of biology, Proteins, Posttranslational modification, Apoptosis, Organelles, Proteasome, Ubiquitin, CBLL1, Mdm2

SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.

Key Points: 
  • SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.
  • Additional details on the presentation are below:
    Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.
  • Nurixs drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
  • Nurixs wholly owned pipeline comprises targeted protein degraders of Brutons tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation.

Moleculin to Present at LD Micro 500 Virtual Investor Conference

Retrieved on: 
Thursday, August 27, 2020
Chemistry, Physical sciences, Natural sciences, Biochemistry, Carbohydrates, Glycosylation, Posttranslational modification

Additionally, the Company will hold 1-on-1 virtual investor meetings at the conference.

Key Points: 
  • Additionally, the Company will hold 1-on-1 virtual investor meetings at the conference.
  • Investors attending the conference virtually who are interested in meeting with Company management should contact their LD Micro representatives.
  • Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
  • Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

NeuBase Therapeutics Reports Financial Results for the Third Fiscal Quarter of 2020

Retrieved on: 
Thursday, August 13, 2020
Branches of biology, RNA, Biology, DNA, Gene expression, Molecular biology, Gene silencing, Posttranslational modification, Oligonucleotide, Sense

These positive pharmacokinetic and pharmacodynamic data position our unique technology to output a vast pipeline of therapeutics to resolve innumerable human diseases.

Key Points: 
  • These positive pharmacokinetic and pharmacodynamic data position our unique technology to output a vast pipeline of therapeutics to resolve innumerable human diseases.
  • We anticipate presenting additional new data with respect to our ongoing progress in the fourth calendar quarter of this year.
  • We expect this to support our R&D and general corporate expenses into the second calendar quarter of 2022, continued Dr. Stephan.
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

NeuBase Therapeutics Strengthens Senior Management Team with Appointment of Industry Veteran William Mann, Ph.D., MBA as Chief Operating Officer

Retrieved on: 
Tuesday, July 28, 2020
Branches of biology, RNA, Biology, DNA, Molecular biology, Epigenetics, Gene silencing, Posttranslational modification, Dietrich Stephan, Oligonucleotide, Sense

Dr. Mann will leverage his decades of experience in the biopharma industry to manage NeuBase operations and advance its strategic goals.

Key Points: 
  • Dr. Mann will leverage his decades of experience in the biopharma industry to manage NeuBase operations and advance its strategic goals.
  • Our goal with this important addition to our team is to ensure the infrastructure within the organization is structured for accelerated growth, said Dietrich Stephan, Ph.D., chief executive officer of NeuBase.
  • Dr. Mann added, "I am honored to join NeuBase, which has already assembled a foundation of impressive leadership.
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate

Retrieved on: 
Wednesday, July 15, 2020
Chemistry, Natural sciences, Physical sciences, Biochemistry, Carbohydrates, Glycosylation, Posttranslational modification

The planned tests are intended to provide additional comparative data of WP1122 and its close analogs.

Key Points: 
  • The planned tests are intended to provide additional comparative data of WP1122 and its close analogs.
  • Management believes the mechanism of action of 2-DG and WP1122 is very different from other drugs being developed for COVID-19.
  • Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
  • Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition, such as WP1122.

Moleculin to Present at the Life Sciences Investor Forum

Retrieved on: 
Tuesday, June 23, 2020
Chemistry, Physical sciences, Natural sciences, Biochemistry, Carbohydrates, Glycosylation, Posttranslational modification

If attendees are not able to join on the day of the conference, an archived webcast will also be made available after the event.

Key Points: 
  • If attendees are not able to join on the day of the conference, an archived webcast will also be made available after the event.
  • It is recommended that investors pre-register for the event using the following link: https://www.lifesciencesinvestorforum.com/login-registration .
  • Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
  • Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition, such as WP1122.